Please ensure Javascript is enabled for purposes of website accessibility

You May Not Know This Cloud Storage Player, but Big Pharma Banks On It

By Motley Fool Staff - Feb 20, 2016 at 2:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Veeva Systems tackles the mountain of data that healthcare companies deal with. Here's how the company is bringing healthcare data into the 21st century.

Veeva Systems (VEEV 3.56%) is the leading company in the life sciences data management space.

In this Industry Focus: Tech video segment, Sean O'Reilly and Kristine Harjes explain exactly what the company does, why that's important, and how it has made a name for itself among Big Pharma players. They also touch upon how long and expensive the drug approval process can be.

A full transcript follows the video.

This podcast was recorded on Feb. 12, 2016. 

Sean O'Reilly: Talk to me about Veeva, particularly their first-mover advantage with everything.

Kristine Harjes: Yeah, that's a huge advantage here. What Veeva does, they're a life sciences data management company. They've got two main parts of the business. You have your core CRM business, which is your customer relationship management, and you've got Veeva Vault, which is a content management system.

O'Reilly: What a name.

Harjes: Yeah, it's very catchy.

O'Reilly: I'm sorry to interrupt, their customers are the Pfizers and the Mercks, and the biotech companies that you're talking about?

Harjes: Yeah, through Vault, actually, they're actually working with 34 of the 50 largest pharmaceutical companies.

O'Reilly: That'll do.

Harjes: Yeah, so Vault, essentially, is a system where you take all of the information about processing a drug's clinical trials and approval records and whatnot, and storing it, sharing it, having it be really secure, and being able to transfer these master files to parties like the FDA.

O'Reilly: I know a few people, in fact, a good friend of mine works for Merck. These are not small amounts of data. The amount of analysis and data tracking that goes into one drug in the simulations and everything, it's huge, I would assume.

Harjes: Yeah, it is a mind-boggling task to get a drug to market. There are estimates now that the cost of getting a drug through approval is $2 billion per drug.

O'Reilly: And this is why our drugs are expensive, folks.

Harjes: Yeah. This process lasts more than a decade usually. So, obviously, with that, you're going to have this tremendous amount of information, so, what do you do with it? You need somebody that can store it, and cloud-based software is a really, really intriguing way of meeting this need.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Veeva Systems Inc. Stock Quote
Veeva Systems Inc.
VEEV
$207.04 (3.56%) $7.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.